EP
CC icon

Eudaimonia Partners’s Chemours CC Stock Holding History

Eudaimonia Partners’s Portfolio CC Stock Details CC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-960
Closed -$27K – 516
2021
Q1 		$27K Buy
960
+18
+2% +$479 0.01% 848
2020
Q4 		$23K Sell
942
-28
-3% -$666 0.01% 818
2020
Q3 		$20K Buy
+970
New +$18.7K 0.01% 790
2020
Q1 		– Sell
-1,185
Closed -$21K – 680
2019
Q4 		$21K Buy
+1,185
New +$19.7K 0.01% 659

Other funds holding CC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Eudaimonia Partners's CC Position: Q2 2021 in Review

Eudaimonia Partners sold out of Chemours (CC) in Q2 2021, closing a stake of 960 shares — an estimated $27K sold.

Eudaimonia Partners first reported a position in CC in Q4 2019 and held it in 4 quarters. The position peaked at $27K in Q1 2021. 449 funds tracked by Wall St. Rank hold CC as of Q2 2021.

  • Eudaimonia Partners reported no remaining Chemours position as of Q2 2021 after selling out during the quarter.
  • Eudaimonia Partners sold 960 Chemours shares in Q2 2021, an estimated $27K.
  • Eudaimonia Partners first reported a position in Chemours in Q4 2019 and held it in 4 quarters.
  • Eudaimonia Partners's Chemours position peaked at $27K in Q1 2021.
  • 449 funds tracked by Wall St. Rank held Chemours as of Q2 2021.

Based on Eudaimonia Partners's 13F filing for Q2 2021, filed 13 Aug 2021.